Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

29.83 -0.38 (-1.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed... 
Via StockStory
Topics Bonds Economy Lawsuit
Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum
FDA approves Amphastar's iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2025 launch. 
Via Benzinga
Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd.
Via ACCESS Newswire
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Amphastar Announces FDA Approval for Iron Sucrose Injection, USP
Via ACCESS Newswire
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q2 Sales Targets, But Stock Soars 6%
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell short of the market’s revenue expectations in Q2 CY2025, with sales falling 4.4% year on year to $174.4 million. Its non-GAAP profit... 
Via StockStory
Amphastar (AMPH) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings Supply Chain
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025
Via ACCESS Newswire
1 of Wall Street’s Favorite Stock to Target This Week and 2 We Find Risky
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7th, 2025
Via ACCESS Newswire
3 Low-Volatility Stocks with Questionable Fundamentals
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
Topics Supply Chain
Fortrea, Azenta, Bio-Techne, 10x Genomics, and Amphastar Pharmaceuticals Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a broad market rally. 
Via StockStory
Topics Stocks World Trade
agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like... 
Via StockStory
Topics Lawsuit World Trade
Amphastar Pharmaceuticals Aims to Quadruple Domestic Manufacturing Capacity at Rancho Cucamonga Headquarters
Via ACCESS Newswire
Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. 
Via StockStory
Topics ETFs Stocks World Trade
1 Healthcare Stock on Our Buy List and 2 to Approach with Caution
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
AMPHASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) – An Undervalued Stock Worth Considering
AMPH ASTAR PHARMACEUTICALS (NASDAQ:AMPH) presents an undervalued opportunity with strong profitability, reasonable financial health, and historical growth, making it a candidate for value investors. 
Via Chartmill
1 Healthcare Stock with Solid Fundamentals and 2 to Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
3 Value Stocks with Questionable Fundamentals
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
AMPHASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) – An Undervalued Stock Worth Considering
AMPH ASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) is an undervalued stock with strong profitability, reasonable financial health, and an attractive valuation, making it a candidate for value investors. 
Via Chartmill
3 Russell 2000 Stocks with Questionable Fundamentals
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these... 
Via StockStory
3 Small-Cap Stocks Walking a Fine Line
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
Evolent Health, Amphastar Pharmaceuticals, Iridium, and Magnite Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +2.0%) as President Trump postponed the planned 50% tariff on European Union imports,... 
Via StockStory
Topics Artificial Intelligence Government Stocks
Generic Pharmaceuticals Stocks Q1 In Review: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs Peers
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Via ACCESS Newswire
AMPHASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) – A Potentially Undervalued Stock Worth Watching
AMPH ASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) offers strong profitability and an undervalued stock price, making it a candidate for value investors. Check the full analysis for details. 
Via Chartmill
This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
 
Via Benzinga
Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference
Via ACCESS Newswire
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q1 Sales Targets
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $170.5 million. Its non-GAAP profit of $0.74... 
Via StockStory
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.